November 20, 2026

FDA Nominee Commits to Mifepristone Safety Study

Dr. Heidi Overton, the nominee for FDA commissioner, has pledged to establish a timeline and clear parameters for a safety study on the abortion drug mifepristone. This commitment was shared by the office of Sen. Josh Hawley, a member of the Senate Health, Education, Labor and Pensions (HELP) Committee. Hawley has been vocal about wanting federal health officials to take responsibility for the delayed assessment of the medication.

Hawley called these developments significant achievements in ensuring a thorough study and considering the reinstatement of important safeguards on mifepristone, which President Biden had previously removed. He emphasized that the FDA must adhere to these promises, and future nominees for FDA commissioner must commit to this agenda to gain his support.

The Trump administration aims to complete a full mifepristone safety study by March 2027. The FDA plans to implement regulatory changes based on the study’s findings by September 2027. These updated safety protocols will apply to both brand-name mifepristone and its generic versions.

The need for a comprehensive study has been fueled by changes made in 2023, when the Biden administration lifted restrictions requiring in-person doctor visits and dispensing for the medication. This shift in policy has prompted continuous scrutiny and calls for federal oversight.

Dr. Overton stated in her Senate committee confirmation questionnaire that the FDA is committed to rapidly completing its ongoing review using appropriate data and experts. The goal is to follow the evidence and make the results as public as legally possible. If confirmed, she supports completing this work swiftly while maintaining scientific integrity.

Furthermore, in March, Hawley encouraged fellow Republicans to support legislation against mifepristone. He pointed out that the drug is nearly always fatal to the unborn child and poses considerable risks to women’s health. The companies behind this drug reportedly profit from its widespread distribution, despite its potential dangers. Hawley highlighted the need for congressional action to address these concerns.

TAGS: